DGAP-News

INJEX Pharma AG: Strategic Financial Group invests in INJEX Pharma AG

DGAP-News: INJEX Pharma AG / Key word(s): Miscellaneous
INJEX Pharma AG: Strategic Financial Group invests in INJEX Pharma AG

17.12.2013 / 11:11

---------------------------------------------------------------------

Corporate News: Strategic Financial Group invests in INJEX Pharma AG

Berlin, December 17, 2013 - INJEX Pharma AG anounces, that Fambrinia Ltd.
(Fambrinia) has taken a significant share in the Berlin based company and
has become the largest shareholder in INJEX Pharma AG. Fambrinia holds the
distribution rights for Injex Pharma products in Russia, Kazachstan,
Azerbaijan, Belorussia and Turkmenistan. The respective contracts have been
signed last Friday. The previously signed term sheet between the parties
was already announced in an ad hoc news by INJEX Pharma last week.

Fambrinia subscribes all newly issued ordinary shares of a 10% capital
increase decided by the Executive Board and authorized by the Supervisory
Board. Following this capital increase, the company's share capital rises
from EUR 3,458,000.00 to EUR 3,803,800.00, divided into 3,803,800 shares at
a nominal value of EUR 1.00 per share. The issue price per share is set at
EUR 1.00. The new shares carry full dividend rights from 1 January 2013.
The new shares will be issued in private placement without pre-emptive
rights.

Furthermore, Fambrinia acquires a majority of the shares currently held by
MMB Medical Marketing Berlin GmbH (MMB), so far the major shareholder of
INJEX Pharma AG. MMB will transfer the most of the sales proceeds as a
shareholder loan to INJEX Pharma AG.

The proceeds from this transaction will mainly be used to reduce the
companies liabilities and to further develop its operations. Upon
consummation of the transaction, Fambrinia will held 40% of INJEX Pharma
shares and become be the major shareholder, followed by MMB holding 14% of
the shares.

'We are very pleased having attracted Fambrinia as a strategic investor,
who will provide us with growth capital as well as with valuable input for
the future development for our products and applications since Fambrinia is
our distributor for the huge markets in CIS countries.' commented Dr.
Thomas Klaue, CEO of INJEX Pharma AG. Dr. Peter Heinrich, Chairman of the
Supervisory Board, adds: 'With this transaction, the Management Board,
which took office in last May, has concluded most of the necessary
reorganization and restructuring of INJEX Pharma and can now focus on our
operating business, mainly on the production development and the expansion
of the international partner and distributor network.'

For further information on INJEX Pharma AG and its subsidiaries, please